Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Swiss Cancer Institute
Swiss Cancer Institute
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
University of Alabama at Birmingham
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
Stanford University
Northwestern University